These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

165 related items for PubMed ID: 29708843

  • 1. Cost-effectiveness of switching from trivalent to quadrivalent inactivated influenza vaccines for the at-risk population in Italy.
    Mennini FS, Bini C, Marcellusi A, Rinaldi A, Franco E.
    Hum Vaccin Immunother; 2018; 14(8):1867-1873. PubMed ID: 29708843
    [Abstract] [Full Text] [Related]

  • 2. Cost-effectiveness analysis of quadrivalent versus trivalent influenza vaccine in Taiwan: A lifetime multi-cohort model.
    Yang MC, Tan EC, Su JJ.
    Hum Vaccin Immunother; 2017 Jan 02; 13(1):81-89. PubMed ID: 27624648
    [Abstract] [Full Text] [Related]

  • 3. Cost-effectiveness evaluation of quadrivalent influenza vaccines for seasonal influenza prevention: a dynamic modeling study of Canada and the United Kingdom.
    Thommes EW, Ismaila A, Chit A, Meier G, Bauch CT.
    BMC Infect Dis; 2015 Oct 27; 15():465. PubMed ID: 26503131
    [Abstract] [Full Text] [Related]

  • 4. Cost-Utility of Quadrivalent Versus Trivalent Influenza Vaccine in Germany, Using an Individual-Based Dynamic Transmission Model.
    Dolk C, Eichner M, Welte R, Anastassopoulou A, Van Bellinghen LA, Poulsen Nautrup B, Van Vlaenderen I, Schmidt-Ott R, Schwehm M, Postma M.
    Pharmacoeconomics; 2016 Dec 27; 34(12):1299-1308. PubMed ID: 27647004
    [Abstract] [Full Text] [Related]

  • 5. Cost-Effectiveness of Quadrivalent versus Trivalent Influenza Vaccine in the United States.
    de Boer PT, Crépey P, Pitman RJ, Macabeo B, Chit A, Postma MJ.
    Value Health; 2016 Dec 27; 19(8):964-975. PubMed ID: 27987647
    [Abstract] [Full Text] [Related]

  • 6. The Clinical Impact and Cost Effectiveness of Quadrivalent Versus Trivalent Influenza Vaccination in Finland.
    Nagy L, Heikkinen T, Sackeyfio A, Pitman R.
    Pharmacoeconomics; 2016 Sep 27; 34(9):939-51. PubMed ID: 27423657
    [Abstract] [Full Text] [Related]

  • 7. Impact of quadrivalent influenza vaccines in Brazil: a cost-effectiveness analysis using an influenza transmission model.
    Crépey P, Boiron L, Araujo RR, Lopez JG, Petitjean A, de Albuquerque Luna EJ.
    BMC Public Health; 2020 Sep 09; 20(1):1374. PubMed ID: 32907562
    [Abstract] [Full Text] [Related]

  • 8. Cost-effectiveness analysis of quadrivalent influenza vaccine versus trivalent influenza vaccine for elderly in Hong Kong.
    You JH, Ming WK, Chan PK.
    BMC Infect Dis; 2014 Nov 25; 14():618. PubMed ID: 25420713
    [Abstract] [Full Text] [Related]

  • 9. From trivalent to quadrivalent influenza vaccines: Public health and economic burden for different immunization strategies in Spain.
    Crépey P, Redondo E, Díez-Domingo J, Ortiz de Lejarazu R, Martinón-Torres F, Gil de Miguel Á, López-Belmonte JL, Alvarez FP, Bricout H, Solozabal M.
    PLoS One; 2020 Nov 25; 15(5):e0233526. PubMed ID: 32437476
    [Abstract] [Full Text] [Related]

  • 10. Cost Effectiveness of Quadrivalent Influenza Vaccines Compared with Trivalent Influenza Vaccines in Young Children and Older Adults in Korea.
    Kim YK, Song JY, Jang H, Kim TH, Koo H, Varghese L, Han E.
    Pharmacoeconomics; 2018 Dec 25; 36(12):1475-1490. PubMed ID: 30251078
    [Abstract] [Full Text] [Related]

  • 11. Cost-effectiveness of quadrivalent influenza vaccine in Hong Kong - A decision analysis.
    You JH, Ming WK, Chan PK.
    Hum Vaccin Immunother; 2015 Dec 25; 11(3):564-71. PubMed ID: 25714506
    [Abstract] [Full Text] [Related]

  • 12. Cost-effectiveness analysis of quadrivalent influenza vaccine in Spain.
    García A, Ortiz de Lejarazu R, Reina J, Callejo D, Cuervo J, Morano Larragueta R.
    Hum Vaccin Immunother; 2016 Sep 25; 12(9):2269-77. PubMed ID: 27184622
    [Abstract] [Full Text] [Related]

  • 13. Cost-effectiveness analysis of quadrivalent influenza vaccination in at-risk adults and the elderly: an updated analysis in the U.K.
    Meier G, Gregg M, Poulsen Nautrup B.
    J Med Econ; 2015 Sep 25; 18(9):746-61. PubMed ID: 25903831
    [Abstract] [Full Text] [Related]

  • 14. Cost Utility of Switching From Trivalent to Quadrivalent Influenza Vaccine in Turkey.
    Amiche A, Tanriover MD, Bellier L, Ugur B, Akin L.
    Value Health Reg Issues; 2021 Sep 25; 25():15-22. PubMed ID: 33485248
    [Abstract] [Full Text] [Related]

  • 15. Cost-effectiveness of quadrivalent versus trivalent influenza vaccine for elderly population in China.
    Jiang M, Li P, Wang W, Zhao M, Atif N, Zhu S, Fang Y.
    Vaccine; 2020 Jan 29; 38(5):1057-1064. PubMed ID: 31787414
    [Abstract] [Full Text] [Related]

  • 16. Switching from trivalent to quadrivalent inactivated influenza vaccines in Uruguay: a cost-effectiveness analysis.
    Bianculli PM, Bellier L, Mangado IO, Pérez CG, Mieres G, Lazarov L, Petitjean A, Dibarboure H, Lopez JG.
    Hum Vaccin Immunother; 2022 Nov 30; 18(5):2050653. PubMed ID: 35344679
    [Abstract] [Full Text] [Related]

  • 17. Cost-effectiveness analysis of different seasonal influenza vaccines in the elderly Italian population.
    Capri S, Barbieri M, de Waure C, Boccalini S, Panatto D.
    Hum Vaccin Immunother; 2018 Jun 03; 14(6):1331-1341. PubMed ID: 29425079
    [Abstract] [Full Text] [Related]

  • 18. Cost-Effectiveness of Routine Childhood Vaccination Against Seasonal Influenza in Germany.
    Scholz SM, Weidemann F, Damm O, Ultsch B, Greiner W, Wichmann O.
    Value Health; 2021 Jan 03; 24(1):32-40. PubMed ID: 33431151
    [Abstract] [Full Text] [Related]

  • 19. Cost-Effectiveness of Quadrivalent Versus Trivalent Influenza Vaccination in the Dutch National Influenza Prevention Program.
    Zeevat F, Crépey P, Dolk FCK, Postma AJ, Breeveld-Dwarkasing VNA, Postma MJ.
    Value Health; 2021 Jan 03; 24(1):3-10. PubMed ID: 33431150
    [Abstract] [Full Text] [Related]

  • 20. Inactivated quadrivalent split-virus seasonal influenza vaccine (Fluarix® quadrivalent): a review of its use in the prevention of disease caused by influenza A and B.
    McKeage K.
    Drugs; 2013 Sep 03; 73(14):1587-94. PubMed ID: 24022123
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.